Senzime AB (publ) (STO: SEZI)

Market Cap	949.26M
Revenue (ttm)	47.04M
Net Income (ttm)	-130.32M
Shares Out	119.71M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,433
Open	7.52
Previous Close	7.52
Day's Range	7.52 - 8.04
52-Week Range	5.00 - 9.60
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 52
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SEZI

Financial Performance

In 2023, NIL.B's revenue was 877.88 million, a decrease of -7.42% compared to the previous year's 948.27 million. Earnings were 39.39 million, a decrease of -61.00%.